Physician profile
Brandy D Maphet
NPI 1932738663
$4,904.00
in general payments reported to CMS, 2019-2025
21 companies · $3,438 in 2025
The $3,438 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,466 · 2025: $3,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,595 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.20 |
| Education | $308.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $979.04 | 2024-2025 | |
| Janssen Biotech, INC. | $698.60 | 2024-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $580.20 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $451.71 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $424.80 | 2024-2025 | Ebglyss, Taltz |
| Genzyme Corporation | $299.09 | 2024-2025 | |
| Ucb, INC. | $294.17 | 2024-2025 | Bimzelx |
| Amgen INC. | $236.75 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $182.55 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $173.30 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.66 | 2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $100.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85.03 | 2025 | Sotyktu |
| Incyte Corporation | $65.60 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $64.77 | 2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.96 | 2024-2025 | Cabtreo, Siliq, Arazlo |
| Sanofi US Services INC. | $36.99 | 2024 | |
| Leo Pharma INC. | $25.17 | 2025 | Anzupgo |
| Springworks Therapeutics, INC. | $21.37 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $19.52 | 2025 | Ycanth |
| Botanix Sb INC | $14.29 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Maphet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.